WELLS FARGO & COMPANY/MN - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,277,087
-34.9%
76,564
+7.8%
0.00%
-100.0%
Q2 2023$1,962,429
+151.2%
71,051
+109.2%
0.00%
Q1 2023$781,172
+193259.4%
33,964
+91694.6%
0.00%
Q4 2022$404
-97.9%
37
-98.4%
0.00%
Q3 2022$19,000
-56.8%
2,344
-58.3%
0.00%
Q2 2022$44,000
-92.9%
5,625
-78.4%
0.00%
Q1 2022$616,000
-55.4%
26,019
-35.5%
0.00%
Q4 2021$1,380,000
+32.4%
40,358
-31.3%
0.00%
Q3 2021$1,042,000
-22.6%
58,729
+95.6%
0.00%
Q2 2021$1,346,000
+35.3%
30,018
-21.9%
0.00%
Q1 2021$995,000
-32.9%
38,435
-47.7%
0.00%
Q4 2020$1,483,000
+188.5%
73,531
+180.2%
0.00%
Q3 2020$514,000
+94.0%
26,244
+75.3%
0.00%
Q2 2020$265,000
-22.7%
14,969
-69.2%
0.00%
Q1 2020$343,000
+44.7%
48,545
+45.0%
0.00%
Q4 2019$237,000
-24.0%
33,478
+28.9%
0.00%
Q3 2019$312,000
+25.8%
25,974
+26.4%
0.00%
Q2 2019$248,000
+21.0%
20,553
+25.9%
0.00%
Q1 2019$205,000
+66.7%
16,329
-11.0%
0.00%
Q4 2018$123,000
-5.4%
18,345
+45.6%
0.00%
Q3 2018$130,000
+46.1%
12,601
-4.6%
0.00%
Q2 2018$89,000
+21.9%
13,205
+54.5%
0.00%
Q1 2018$73,000
-36.5%
8,545
+55.4%
0.00%
Q4 2017$115,000
-32.0%
5,500
-42.5%
0.00%
Q3 2017$169,000
+152.2%
9,565
+60.8%
0.00%
Q2 2017$67,0000.0%5,948
+14.0%
0.00%
Q1 2017$67,000
-41.7%
5,2190.0%0.00%
Q4 2016$115,0005,2190.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$56,331,20918.32%
Kynam Capital Management, LP 1,375,000$31,625,0004.08%
BVF INC/IL 3,775,900$86,845,7003.18%
Cormorant Asset Management, LP 1,700,000$39,1002.58%
RTW INVESTMENTS, LP 4,600,799$105,818,3772.20%
Ghost Tree Capital, LLC 225,000$5,175,0001.53%
683 Capital Management, LLC 791,000$18,193,0001.36%
Ikarian Capital, LLC 211,400$4,862,2001.10%
Ikarian Capital, LLC 211,400$4,862,2001.10%
SILVERARC CAPITAL MANAGEMENT, LLC 105,486$2,426,1781.00%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders